Emerging data suggest Retatrutide , a dual agonist targeting both incretin and glucose-dependent insulinotropic polypeptide , may offer a promising step forward for body management . Early patient https://getretatrutideaustralia.com/blog/retatrutide-weight-loss-revolution-2026